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CD4CD25 regulatory T cells (CD25 Tregs) play a key role in immune regulation. Since hepatitis C virus
(HCV) persists with increased circulating CD4CD25 T cells and virus-specific effector T-cell dysfunction, we
asked if CD4CD25 T cells in HCV-infected individuals are similar to natural Tregs in uninfected individuals
and if they include HCV-specific Tregs using the specific Treg marker FoxP3 at the single-cell level. We report
that HCV-infected patients display increased circulating FoxP3 Tregs that are phenotypically and function-
ally indistinguishable from FoxP3 Tregs in uninfected subjects. Furthermore, HCV-specific FoxP3 Tregs
were detected in HCV-seropositive persons with antigen-specific expansion, major histocompatibility complex
class II/peptide tetramer binding affinity, and preferential suppression of HCV-specific CD8 T cells. Trans-
forming growth factor  contributed to antigen-specific Treg expansion in vitro, suggesting that it may
contribute to antigen-specific Treg expansion in vivo. Interestingly, FoxP3 expression was also detected in
influenza virus-specific CD4 T cells. In conclusion, functionally active and virus-specific FoxP3 Tregs are
induced in HCV infection, thus providing targeted immune regulation in vivo. Detection of FoxP3 expression
in non-HCV-specific CD4 T cells suggests that immune regulation through antigen-specific Treg induction
extends beyond HCV.
Hepatitis C virus (HCV) is a highly persistent human patho-
gen that causes chronic necroinflammatory liver disease with
progression to liver failure and cancer (25, 31). While T cells
play a critical role in HCV clearance (24, 53), the virus gener-
ally persists, along with impaired antiviral effector T-cell re-
sponses (13, 59, 63, 69). While the precise underlying mecha-
nisms for HCV persistence and disease pathogenesis are not
fully defined, a role for CD4CD25 regulatory T cells
(CD25 Tregs) has been proposed based on increased circu-
lating CD4CD25 T cells that can suppress HCV-specific T
cells in HCV-infected patients (10, 12, 48, 54). CD25 Tregs
are a subset of naturally occurring, thymus-derived CD4 reg-
ulatory T cells that highly express CD25 (the interleukin-2
[IL-2] receptor alpha chain) and play a critical role in immune
tolerance to self and nonself antigens (27, 44, 49, 51). The role
of CD25 Tregs in immune regulation has been demonstrated
in animal models of organ-specific autoimmune diseases, in
which pathology is precipitated by their depletion and amelio-
rated by their reconstitution (52). The key marker of CD25
Tregs is the forkhead/winged helix family transcription factor
FoxP3 (70). Impaired FoxP3 gene expression results in severe
autoimmunity in human immune dysregulation, polyendocri-
nopathy, enteropathy, X-linked syndrome (8, 67) and in Scurfy
mice (11); furthermore, forced FoxP3 expression in FoxP3 T
cells confers regulatory properties in vitro (21, 65).
CD25 Tregs may also contribute to pathogen-specific im-
mune regulation in viral infections, including those with hep-
atitis B and C, herpes simplex, Friend leukemia, and dengue
viruses (14, 22, 23, 34, 36, 45, 47). However, since CD25 is
expressed by both activated and regulatory T cells, CD25
Tregs may be more precisely defined by FoxP3 in inflammatory
settings, including viral infections. Furthermore, it is not
known if CD25 Tregs induced during viral infection are dis-
tinct from natural Tregs or if they recognize viral antigens.
Here, we report that CD25 FoxP3 Tregs indistinguishable
from natural Tregs are upregulated in HCV-infected persons.
We also show that HCV can prime virus-specific FoxP3 Tregs
with antigen-specific expansion and suppression of HCV-spe-
cific CD8 T cells. We also show that FoxP3 extends to non-
HCV-specific CD4 T cells, suggesting a more global role for
antigen-specific Tregs in immune regulation beyond that for
HCV infection.
MATERIALS AND METHODS
Study subjects. HCV-seropositive subjects with chronic viremia (designations
beginning with C) or spontaneous resolution of infection (designations beginning
with R) and HCV-seronegative uninfected controls were recruited at the Phila-
delphia Veterans Affairs Medical Center and the Hospital of the University of
Pennsylvania with informed consent approved by the institutional review boards.
Persons with human immunodeficiency virus (HIV) or hepatitis B virus coinfec-
tion, active immunosuppressive or antiviral therapy, autoimmune or alcoholic
hepatitis, or conditions precluding phlebotomy as previously described (54, 55)
were excluded. HCV viremia was quantified by Roche COBAS Amplicor HCV
Monitor or TaqMan HCV (Roche Diagnostics, Indianapolis, IN) and defined as
“high” when it was above the upper limit of the HCV Monitor assay (850,000
IU/ml).
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Fluorescent antibodies. All antibodies were purchased from Becton Dickinson
(San Jose, CA) or BD Pharmingen (San Diego, CA) except for anti-glucocorti-
coid-induced tumor necrosis factor (TNF) receptor (GITR) (clone110416) from
R&D Systems (Minneapolis, MN), anti-transforming growth factor  (TGF-;
clone TB21) from IQ Products (Groningen, The Netherlands), and anti-FoxP3
(clone PCH101) from eBioscience (San Diego, CA).
Recombinant HCV proteins and peptides. Recombinant HCV proteins
(known to stimulate CD4 T cells) and control superoxide dismutase (SOD) were
kindly provided by Michael Houghton (Chiron Corporation, Emeryville, CA)
(15, 56). Antigenic peptides (optimum and overlapping 15-mers) were synthe-
sized as described previously (28, 54).
PBMC. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-
Histopaque (Sigma Chemical Co., St. Louis, MO) as described previously (28, 54).
Major histocompatibility complex (MHC)/peptide tetramers. HLA-A2-re-
stricted class I tetramers were produced at the University of Oxford and used as
described previously (26, 55). HLA-DR4-restricted HCV-specific (HCV 1248,
GYKVLVLNPSVAATL; HCV1770, SGIQYLAGLSTLPGNPAIASL) and in-
fluenza virus-specific hemagglutinin (HA; PRYVKQNTLKLAT) class II tetra-
mers were synthesized at the Benaroya Research Institute and used at 0.5
g/sample as described previously (17, 42).
Immunophenotyping by flow cytometry (fluorescence-activated cell sorting
[FACS]). Cells were stained with fluorescent antibodies, acquired using
FACSCalibur or FACSCanto (Becton Dickinson) and analyzed with Cell
Quest (Becton Dickinson) or FlowJo (Tree Star, Inc., San Carlos, CA) soft-
ware (54, 55), gating on lymphoid cells based on forward and side scatter
profile. CD25 positivity was defined by an isotype-defined cutoff (99.9%).
High or intermediate CD25 expression (CD25high or CD25int) was defined at
a threshold where most CD4-negative cells lost CD25 expression (Fig. 1A).
FoxP3 positivity was defined at an isotype-defined threshold where most
CD4-negative cells became Foxp3 negative. Since delayed staining or cryo-
preservation resulted in marked reduction in CD25high T-cell frequency (data
not shown), all ex vivo stainings were performed with freshly isolated PBMC.
Cell sorting. CD4CD25high, CD4CD25int, and CD4CD25 subsets were
sorted by FACSVantage (Becton Dickinson) at the BSL-3 FACS Core Facility at
the Children’s Hospital of Philadelphia to 90% purity. CD4CD25 (80%
CD25high) and CD4CD25 (90% CD25) T-cell subsets were also sorted by
autoMACS using the CD4CD25 regulatory T-cell isolation system (Miltenyi
Biotec Inc., Auburn, CA). Typically, 2 to 5 million CD4CD25high or
CD4CD25 T cells were isolated from 200 to 300 million PBMC. Sorting for
MHC-II tetramer cells was performed using antiphycoerythrin beads (Miltenyi
Biotech, Auburn, CA) as described previously (17, 33).
Cytokine analysis. Intracellular cytokine staining was performed after 5 h of
stimulation with or without 10 ng/ml phorbol 12-myristate 13-acetate (PMA;
Sigma Chemical Co.), 200 ng/ml ionomycin (Sigma Chemical Co.), and brefeldin
A (1 l/ml) with a Cytofix/Cytoperm kit (BD Pharmingen) (15, 40). Culture
supernatants of cells stimulated with PMA-ionomycin or HCV antigens (up to
72 h) were also examined for Th1/Th2 cytokines using the Cytometric Bead
Array Th1/Th2 cytokine kit (BD Pharmingen) and for TGF- using the human
TGF-1 immunoassay kit (R&D Systems).
Ex vivo Treg suppression assay. FACS-sorted CD4CD25high or
CD4CD25int “suppressor” T cells were cocultured in triplicate with autologous
CD4CD25 “responders” (50,000 cells/well) in 96-well plates at suppressor/
responder ratios of 1:0, 1:1, 0.4:1, 0.2:1, and 0:1 for 3 days with media alone, 2
g/ml phytohemagglutinin (PHA; Sigma Chemical Co.), or 1 g/ml plate-bound
anti-CD3 (clone UCHT1; BD Pharmingen) with 2 g/ml anti-CD28 (clone
CD28.2; BD Pharmingen) before 16 h of [3H]thymidine (1 Ci/well) uptake (15,
54). Proliferation was expressed as a stimulation index (SI): the mean cpm in
stimulated wells divided by the mean cpm in unstimulated wells. T-cell prolifer-
ation in each coculture was normalized by proliferation in CD4CD25 T cells
alone and compared to the final CD4CD25high T-cell content in sorted cells, as
verified by FACS.
HCV-specific FoxP3 Treg cultures. Treg cultures were established by stim-
ulating PBMC (with or without carboxyfluorescein diacetate succinimidyl ester
[CFSE] labeling) for 14 days with HCV (10 g/ml) or control proteins in the
presence of 10 g/ml anti-CD28 (BD Bioscience) and 1,000 U/ml recombinant
IL-2 (rIL-2), followed by twice weekly rIL-2 (with or without weekly TGF-). In
select cultures, 10 ng/ml recombinant TGF- (R&D Systems) or 1 M TGF-
type I receptor kinase inhibitor (SD-208) (kindly provided by Linda Higgins,
Scios Inc., Fremont, CA) (29, 62) was added. The cutoff for FoxP3 expression
was defined by the isotype control (data not shown).
Suppression assay with in vitro-expanded Tregs. CD4CD25 (eTreg) and
CD4CD25 (eCD25) subsets were sorted from 2-week Treg cultures using
the CD4CD25 regulatory T-cell isolation system (Miltenyi Biotec Inc.).
Sorted cells were added to autologous PBMC and stimulated for 7 days with
HCV peptides (2 M) or 1 g/ml plate-bound anti-CD3 with 2 g/ml soluble
anti-CD28 before FACS analysis.
FoxP3 mRNA by real-time PCR. Total RNA was extracted with an RNeasy kit
(Qiagen Inc., Valencia, CA), reverse transcribed, and analyzed by real-time PCR
for FoxP3 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expres-
sion with specific primer/probe sets (Applied Biosystems, Foster City, CA),
normalizing FoxP3 expression relative to GAPDH.
Microarray analysis. Total RNA preparations from FACS-sorted
CD4CD25high T cells from four HCV-infected and four uninfected subjects
were analyzed at the University of Pennsylvania Microarray Core Facility using
the Human Genome U133 Plus 2.0 Array GeneChip (Affymetrix, Santa Clara,
CA). The probe set intensities and absent/present/marginal flags were calculated
using GC-robust multiarray analysis and Affymetrix algorithms as implemented
in Arrayassist Lite (Stratagene, La Jolla, CA). Significance analysis of microar-
rays (SAM version 2.1; Stanford University, Palo Alto, CA) was performed on
18,207/54,675 probe sets that were flagged as “present” in at least 2/8 samples,
resulting in 5 probe sets with at least a twofold difference between HCV-infected
and uninfected samples and a false-discovery rate of 36%.
Statistics. Clinical and immunological parameters were compared with the
nonparametric Mann-Whitney U or Kruskal-Wallis test. Differences in pheno-
type and cytokine profile between T-cell subsets were compared by the nonpara-
metric Wilcoxon signed-rank and Friedman tests. Correlations were tested for
statistical significance by Spearman rank correlation.
RESULTS
HCV persists with increased frequencies of CD4CD25high
FoxP3 Tregs. Since the regulatory phenotype of
CD4CD25 T cells correlates with the intensity of CD25
expression (5, 6), we first differentiated between CD4 T cells
with high and intermediate levels of CD25 expression
(CD25high versus CD25int) (Fig. 1A), as described in Materials
and Methods. As shown in Fig. 1B, HCV-infected patients
displayed significantly greater CD4CD25high T-cell frequency
but not CD4CD25int T-cell frequency than uninfected sub-
jects. Notably, the increased CD25high/CD25int CD4 T-cell ra-
tio was associated with high HCV RNA titers above the upper
limit of detection (850,000 IU/ml) (Fig. 1C), suggesting that
the balance between CD25high regulatory and CD25int acti-
vated effector T cells contributes to viremic control.
CD4CD25high T cells were highly enriched for FoxP3 protein
expression regardless of HCV infection, compared to
CD4CD25int or CD4CD25 T cells (means of 58% versus
6% versus 1%, respectively; P 0.001) (Fig. 1D), as well as for
FoxP3 mRNA (data not shown). Overall, CD4CD25high and
FoxP3 T-cell frequencies were tightly correlated (R  0.76;
P  0.007) (Fig. 1E). Importantly, FoxP3 T-cell frequency
was significantly greater among HCV-infected subjects than
uninfected subjects in total lymphoid cells (P  0.013) and in
CD4 T cells (P  0.028) (Fig. 1F). Thus, HCV persistence is
associated with increased circulating CD25high FoxP3 Tregs,
rather than CD25 FoxP3 effector T cells.
FoxP3 Tregs in HCV-infected patients display a pheno-
type, cytokine profile, and gene expression pattern similar to
those of FoxP3 Tregs in uninfected subjects. CD25high
FoxP3 T cells in HCV-infected and uninfected subjects
displayed similar phenotypes, expressing higher levels of
CD45RO (98%), CD62L (91%), cytotoxic T-lymphocyte anti-
gen 4 (CTLA4; 95%), and HLA-DR (79%) than CD25high
FoxP3 and CD25 FoxP3 subsets (Fig. 2A). Despite con-
stitutive expression reported in murine Tregs (43), GITR was
expressed only in a minority of FoxP3 T cells (14%), although
at greater levels than in FoxP3 T cells. In addition, FoxP3 T
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cells in HCV-infected and uninfected subjects were mostly
negative for CD127 (IL-7 receptor ), as reported for natural
Tregs (32, 50).
FoxP3 T cells displayed an anergic cytokine profile follow-
ing PMA-ionomycin stimulation regardless of HCV status
(Fig. 2B and C), with minimal gamma interferon (IFN-	) or
IL-2 production. Interestingly, significant TNF- production
was observed in FoxP3 T cells, although less than in FoxP3
T cells. FoxP3 T cells were also mostly negative for Th2 or
regulatory cytokines such as IL-4, IL-10, and TGF-; however,
IL-10 was slightly more frequently detected among FoxP3 T
cells than among FoxP3 CD4 T cells (means, 2.1% for
CD25 FoxP3 versus 0.9% for CD25 FoxP3 versus 0.3%
for CD25FoxP3; P  0.0025 by the Friedman test). Further
cytokine analysis by cytokine bead array or enzyme-linked im-
munosorbent assay failed to show significant IL-10 and TGF-
production from CD4CD25 T cells sorted by magnetic
beads and stimulated with PMA-ionomycin or HCV-derived
proteins, even with longer durations of stimulation (data not
shown). Notably, FoxP3 cells within sorted CD4CD25 T
cells showed intermediate levels of IFN-	, IL-2, and TNF-
production compared to FoxP3 T cells within sorted
CD4CD25 T cells, consistent with partial cytokine suppres-
sion by FoxP3 T cells contained within the sorted
CD4CD25 T-cell subset.
Finally, comparing the global gene expression profiles of
FACS-sorted CD4CD25high T cells (90% pure) from four
HCV-infected and four uninfected subjects using Affymetrix
FIG. 1. Increased CD4CD25high T-cell frequency in HCV-infected subjects reflects increased FoxP3 CD4 T-cell frequency. (A) Represen-
tative staining characteristics and gating strategies are shown for CD25high, CD25int, and CD25 CD4 T-cell subsets in PBMC (gating on lymphoid
cells based on forward and side scatter characteristics). CD25 positivity was defined by a fluorescence cutoff below which 99.9% of isotype-stained
cells were negative. CD4CD25 T cells were separated into CD25high or intermediate cells at a point where most CD4-negative cells lost CD25
expression. (B, top) CD4CD25high T-cell frequencies, expressed as percentages, in 35 chronically HCV-infected (HCV) and 15 uninfected
subjects (HCV) (mean, 2.6% versus 2.0%). (Bottom) Percentages of CD4CD25int T cells in HCV-infected and uninfected subjects (mean,
18.6% versus 17.1%). Horizontal bars indicate mean values. (C) Ratios between CD4CD25high and CD4CD25int T-cell frequencies in
HCV-infected patients with HCV RNA titers below or above 850,000 IU/ml (the upper limit of the HCV reverse transcription-PCR assay) (mean,
0.17 versus 0.11). (D) Representative FACS density plots showing intracellular FoxP3 protein expression primarily in CD25 lymphocytes ex vivo.
The bar graph shows mean % FoxP3 cells among CD4CD25high, CD4CD25int, and CD4CD25 T-cell subsets (58% versus 6% versus 1%;
P  0.001 [Friedman test]). There were no differences in % FoxP3 expression between the chronically HCV-infected (n  12) and uninfected (n 
8) subjects for any of the T-cell subsets (P not significant). Error bars indicate standard deviations. Similar patterns were shown for FoxP3 mRNA
expression in FACS-sorted CD4CD25high, CD4CD25int, and CD4CD25 T cells (data not shown). (E) Correlation between circulating FoxP3
and CD4CD25high T-cell frequencies (R  0.76; P  0.007 [Spearman rank correlation]). Gray circles represent data points from chronically
HCV-infected subjects, and unfilled squares represent data points from uninfected controls. (F) Chronically HCV-infected patients (n  14) display
greater FoxP3 T-cell frequencies ex vivo than uninfected controls (n 9) (mean % FoxP3 per lymphoid cell, 3.1% versus 2.3%; P 0.013; mean %
FoxP3 per CD4 T cell, 5.5% versus 3.7%; P  0.028 [Mann-Whitney U]). Multicolor plots show the expression of FoxP3 in CD4 T cells.
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Human Genome U133 Plus 2.0 Array analysis, we found only
5/54,675 probe sets that differed by more than twofold, with a
36.3% false-discovery rate (Table 1). Collectively, these data
indicate that CD25high FoxP3 T cells from HCV-infected and
uninfected subjects are indistinguishable in their phenotypes,
cytokine profiles, and levels of gene expression.
CD4CD25high T cells are hypoproliferative and suppress
CD4CD25 cell proliferation in a dose-dependent manner
following anti-CD3/anti-CD28 and PHA stimulation. The sup-
pressive capacities of FACS-sorted CD4CD25high T cells
from HCV-infected and uninfected subjects against autologous
CD4CD25 responder T cells were tested at various regula-
tor/responder ratios. As shown in Fig. 3A, CD4CD25high T
cells from HCV-infected and uninfected subjects were hy-
poproliferative in isolation and inhibited proliferation of au-
tologous CD4CD25 T cells in a dose-dependent manner
upon PHA as well as CD3/CD28 stimulation. By contrast,
CD4CD25int T cells were less suppressive than
CD4CD25high T cells and even enhanced proliferation mark-
edly following CD3/CD28 stimulation (Fig. 3B). Relative T-
cell proliferation in each coculture showed a tight inverse cor-
relation with coculture CD4CD25high T-cell content, as
calculated from the purity of sorted CD4CD25high T cells
(Fig. 3C). Thus, CD4CD25high T cells from HCV-infected
FIG. 2. FoxP3 CD4 T cells from HCV-infected and uninfected subjects display similar phenotype and anergic cytokine profiles. (A) Mean
percentages of CD45RO, CD62L, intracellular (IC) CTLA4, HLA-DR, CD127, and GITR cells in three CD4 T-cell subsets (FoxP3
CD25high, FoxP3 CD25high, and FoxP3 CD25) are shown, with standard deviations indicated by error bars (HCV, infected subjects; HCV,
uninfected controls) based on data from 14 HCV and 7 HCV subjects. No significant differences between HCV-infected and uninfected subjects
for each of these markers are observed. (B) Mean percentages of cytokine cells are shown within FoxP3 CD25, FoxP3 CD25, and FoxP3
CD25 CD4 T-cell subsets following PMA-ionomycin stimulation. Error bars indicate standard deviations. Cytokine profiles for FoxP3 CD25
and FoxP3 CD25 CD4 T cells were determined in the autoMACS-sorted CD4CD25 T-cell subset; cytokine profiles for FoxP3 C25 T cells
were determined in the autoMACS-sorted CD4CD25 T-cell subset. (C) Representative FACS density plots for intracellular cytokine staining
(IFN-	, IL-2, IL-4, IL-10, TGF-, and TNF-) following PMA-ionomycin stimulation in FoxP3 CD25, FoxP3 CD25, and FoxP3 CD25
T-cell subsets from an HCV-infected subject. Longer stimulation with PMA-ionomycin or stimulation with HCV-derived proteins did not enhance
IL-10 or TGF- production by sorted CD4CD25 T-cell subsets based on cytokine bead array (IL-10) or enzyme-linked immunosorbent assay
(TGF-) (data not shown).
TABLE 1. Genes differentially expressed in CD4CD25high T cells sorted from HCV-infected and uninfected subjects using Affymetrix
Human Genome U133 Plus 2.0 Array GeneChipa
Affymetrix identification Gene title Gene designation Fold changeHCV/HCV
False-discovery
rate (%)
218016_s_at RNA polymerase III (DNA directed) polypeptide E (80 kDa) gene POLR3E 2 0
228077_at Hypothetical protein MGC3207 gene MGC3207 0.5 36.3
212296_at Proteasome (prosome, macropain) 26S subunit non-ATPase 14
gene
PSMD14 0.5 36.3
232793_at Immunoglobulin superfamily member 4 gene IGSF4 0.5 36.3
206363_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) MAF 0.4 36.3
a Only 5/54,675 probe sets showed significant differential expression between CD4CD25high T cells sorted from four HCV-infected and four uninfected subjects by
at least twofold and with a 36.3% false-discovery rate.
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and uninfected subjects displayed similar levels of dose-depen-
dent suppression of CD4CD25 T cells upon polyclonal stim-
ulation.
Increased FoxP3 T cells in PBMC of HCV-seropositive
subjects following HCV-specific stimulation in vitro. To deter-
mine if FoxP3 T cells can be expanded in an antigen-specific
manner, PBMC of HCV-seropositive persons were cultured
with recombinant HCV or control proteins, high-dose rIL-2,
and anti-CD28 as previously reported for polyclonal Treg ex-
pansion (20, 60). As shown in Fig. 4, FoxP3 expression was
detected in divided (i.e., CFSE-low) as well as undivided
(CFSE-high) CD4 T cells from HCV-seropositive subjects fol-
lowing in vitro stimulation. While robust cell division was ob-
served in all cultures with high-dose rIL-2 and CD28 costimu-
lation, increased expansion of CFSE-low FoxP3 T cells was
detected in some patients following in vitro stimulation with
HCV antigens compared to that with negative control SOD.
For example, in subject C107, FoxP3 Tregs expanded vigor-
ously with HCV NS3/4 (5.3%) or NS5 (6.1%) but not SOD
(1.8%). FoxP3 Tregs could also be expanded by HCV-specific
stimulation from HCV-resolved subjects, as shown for R58
(Fig. 4A), but not in HCV-seronegative controls (data not
shown). Interestingly, tetanus toxoid also promoted FoxP3
Treg expansion, suggesting that antigen-specific Treg expan-
sion may extend beyond HCV. Antigen-specific FoxP3 Treg
expansion tended to increase in the presence of recombinant
TGF- in subjects C98 (all antigens), C107 (NS5 and tetanus
toxoid), and R58 (NS5). Conversely, Treg expansion was re-
duced by TGF- inhibition in subjects C107 (NS3/4, NS5) and
R58 (NS3/4, NS5, tetanus toxoid), consistent with a role for
TGF- in FoxP3 Treg expansion in vitro.
HCV-expanded FoxP3 Tregs displayed an anergic cytokine
profile without HCV-specific IFN-	 and TNF- expression
(Fig. 4B), suggesting that they are not FoxP3 effector T cells.
They also did not express IL-2 or IL-10 (data not shown).
Finally, HCV-expanded FoxP3 Tregs resembled natural
Tregs in their phenotype, with increased CD25, CTLA4, HLA-
DR, CD45RO, and GITR expression compared to FoxP3
CD4 T cells (Fig. 4C). Collectively, these results show that
virus-specific FoxP3 Tregs can be expanded by antigen-spe-
cific stimulation in vitro.
HCV-specific FoxP3 Tregs demonstrated by class II MHC/
peptide tetramer binding. The antigen specificity of expanded
FoxP3 Tregs was examined more directly by using class II
peptide tetramers specific for DRB1*04-restricted CD4 T-cell
epitopes derived from HCV (NS3 1248, NS4 1770) and influ-
enza virus HA. Antigen specificities for these class II tetramers
were confirmed with peptide-specific short-term T-cell lines
(Fig. 5A and B). As shown in Fig. 5C, NS3 1248- and NS4
1770-specific class II tetramer CD4 T cells could be expanded
from PBMC of HCV-seropositive persons with our Treg ex-
pansion method using antigen, high-dose rIL-2, and CD28
costimulation. For example, recombinant HCV NS3/4 protein
promoted the expansion of HCV-specific but not influenza
virus-specific class II tetramer T cells (0.8% for HCV 1248,
2.9% for HCV 1770, and 0.1% for influenza virus HA). Im-
portantly, FoxP3 was expressed in 44% of expanded HCV
1770-specific CD4 T cells, with a further increase to 90% in the
presence of TGF-. Antigen-specific FoxP3 Treg induction
was not limited to HCV since FoxP3 was also expressed in Flu
HA tetramer CD4 T cells with antigen-specific expansion in
vitro (Fig. 5D).
Finally, the presence of HCV-specific FoxP3 Tregs was
examined directly ex vivo using class II tetramers in freshly
isolated PBMC. As shown in Fig. 6A, exclusion of CD14
monocytes and CD19 B cells reduced the nonspecific back-
ground staining for non-CD4 T cells while maintaining specific
binding to CD4 T cells in DRB1*04 subjects (Fig. 6A). No-
FIG. 3. CD4CD25high T cells from HCV-infected and uninfected subjects display similar levels of dose-dependent suppression following
polyclonal stimulation. (A and B) Proliferative capacities of CD4CD25 responder cells alone and with autologous FACS-sorted CD4CD25
T-cell subsets following PHA or anti ()-CD3/anti-CD28 stimulation at CD25/CD25 T-cell ratios of 1:0, 1:1, 0.4:1, 0.2:1, and 0:1. The y axis
shows the SIs from CD25/CD25 cocultures divided by the SI from CD4CD25 T cells stimulated alone. The graphs represent data from three
chronically HCV-infected and two uninfected control subjects. (C) Percent proliferation (relative to that for CD4CD25 responder T cells
stimulated alone) shows a tight inverse correlation with the actual CD4CD25high T-cell content in each coculture. Values were calculated based
on the purity of the FACS-sorted CD4CD25high subset. (Top) PHA. (Bottom) Anti-CD3/anti-CD28.
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tably, FoxP3 expression was detected at a low level in a subset
of HCV 1770 tetramer CD4 T cells in HLA DRB1*04
HCV-seropositive subjects directly ex vivo (Fig. 6B) or follow-
ing further enrichment (Fig. 6C and D) as reported previously
(17, 33). However, FoxP3 was also expressed in influenza virus
HA-specific CD4 T cells (Fig. 6B), consistent with the notion
that FoxP3 expression is a global characteristic of antigen-
specific CD4 T cells.
Dose-dependent suppression of HCV-specific CD8 T cells by
HCV-specific CD25 Tregs. To confirm that HCV-expanded
FoxP3 T cells are indeed Tregs with immunity-suppressive
function. we tested their capacity to suppress HCV-specific
CD8 T cells. This involved the selection of HCV-seropositive
subject R23, who had HCV NS3-specific CD8 T cells that were
readily detectable by class I MHC/peptide tetramers ex vivo
(Fig. 7A) as well as efficient HCV NS3/4-specific FoxP3 Treg
expansion in vitro (Fig. 7B, top) and therefore yielded suffi-
cient CD4CD25 (eTregs) and control CD4CD25
(eCD25) cells after magnetic bead sorting (Fig. 7B, bottom).
The sorted eTregs and eCD25 T cells were added to autol-
ogous peripheral blood lymphocytes (PBL) and stimulated
with HCV-derived overlapping 15-mer peptide pools to acti-
vate HCV-specific eTregs as well as effector CD4 and CD8 T
cells.
As shown in Fig. 7C, HCV-specific CD8 T-cell expansion
was suppressed in a dose-dependent manner with the addition
of HCV-specific eTregs. Comparable levels of suppression
were noted for eTregs expanded with and without TGF-. The
reduction in CD8 T-cell expansion was less dramatic when
PBMC/eTreg cocultures were stimulated with NS5B peptides
FIG. 4. HCV-specific expansion of FoxP3 Tregs in vitro from HCV-seropositive persons. (A) Antigen-specific expansion with CFSE dilution
and FoxP3 expression (gated on CD4 T cells) by FACS in CFSE-labeled PBMC following stimulation with SOD, recombinant HCV NS3/4 and
NS5 proteins, and tetanus toxoid in the presence of 1,000 U/ml rIL-2 and 10 g/ml of soluble anti-CD28 alone (TGF-), with 10 ng/ml TGF-
(TGF) or 1 M SD-208, a type I receptor kinase inhibitor which inhibits TGF- signaling (i-TGF). Results are shown for three representative
HCV-seropositive subjects: C98 and C107, with chronic infection, and R58, with spontaneous HCV clearance. Numbers in the upper left quadrants
represent percentages for FoxP3 CFSElow CD4 cells (i.e., expanded FoxP3 CD4 T cells). Increased FoxP3 CFSElow cell frequencies at least
1% above the background for SOD are underlined. (B) Percentages of IFN-	 and TNF- production by intracellular cytokine staining following
HCV NS3/4 and PMA-ionomycin stimulation of FoxP3 and FoxP3 CD4 T cells in PBMC cultures stimulated for 14 days with recombinant HCV
NS3/4 protein with rIL-2 and anti-CD28. (C) Phenotypes of FoxP3 and FoxP3 CD4 T cells in 14-day Treg cultures expanded with HCV NS3/4
protein, high-dose rIL-2, and anti-CD28.
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or anti-CD3/anti-CD28. Since these eTregs were initially ex-
panded with NS3/4 protein, this suggests that antigen-specific
Tregs may suppress more efficiently when stimulated in an
antigen-specific manner. Finally, HCV-specific CD8 T-cell
suppression by HCV-specific Tregs was confirmed by class I
MHC/peptide tetramer staining, which showed a dose-depen-
dent suppression of HCV NS3 1406-specific CD8 T-cell expan-
sion in the presence of eTregs (Fig. 7D). HCV 1406-specific
CD8 T-cell expansion was not efficiently suppressed by the
negative control eCD25 T cells. These results suggest that
HCV-specific FoxP3 Tregs can be expanded from HCV-se-
ropositive persons with antigen-specific regulatory function.
DISCUSSION
CD25 Tregs represent 5 to 10% of circulating CD4 T cells
in mice and healthy humans (6, 51). Hypoproliferative and
suppressive in vitro, these low-frequency T cells nonetheless
mediate immune tolerance to self- and nonself antigens in vivo
(27, 44, 49, 51). Tregs also regulate immunity to infectious
pathogens, as shown in small-animal models including murine
herpesvirus (58), Friend leukemia virus (19, 45), and Leishma-
nia major (7) models. While the role of Tregs in human infec-
tions cannot be as directly assessed, HCV presents a compel-
ling scenario for Treg involvement given its high rate of
persistence with increased CD4CD25 T-cell frequencies,
ongoing necroinflammatory liver disease, and virus-specific ef-
fector T-cell dysfunction (10, 12, 48, 54). In this study, we asked
(i) whether true Tregs (rather than activated T cells) are up-
regulated in HCV-infected subjects using the specific marker
FoxP3, (ii) whether FoxP3 Tregs in HCV-infected subjects
differ from those in uninfected subjects, and (iii) whether
HCV-specific FoxP3 Tregs can be induced, thus providing
virus-specific immune regulation.
Both CD4CD25high and FoxP3 T cells were significantly
upregulated in HCV-infected subjects in our study. FoxP3 was
expressed in CD25high rather than CD25int CD4 T cells regard-
less of HCV infection, resulting in a tight correlation between
FoxP3 and CD25high CD4 T-cell frequencies (R  0.76; P 
0.007). Thus, HCV infection was associated with a preferential
increase in FoxP3 Tregs rather than activated CD25 effector
T cells. However, there was no significant difference between
FoxP3 Tregs from HCV-infected and uninfected subjects ex
vivo. First, FoxP3 CD25high T cells displayed an activation
phenotype similar to that for natural Tregs regardless of HCV
status: mostly positive for CD45RO, CD62L, HLA-DR, and
CTLA4 but not CD127 (18, 32, 50). Second, FoxP3 Tregs
from HCV-infected and uninfected subjects both displayed an
anergic cytokine profile, with little to no expression of regula-
tory cytokines IL-10 and TGF-. Therefore, FoxP3 Tregs in
our subjects differed from IL-10-producing Tr1 cells or TGF-
-producing Th3 cells with IL-10- or TGF--dependent im-
mune regulation (4, 12, 30), previously described in HCV in-
fection (12, 35, 63). Third, minimal differences were found in
global gene expression analysis comparing FACS-sorted
CD4CD25high T cells from HCV-infected and uninfected
subjects. Finally, the T-cell-suppressive capacities of FoxP3
Tregs for HCV-infected and uninfected patients were similar
FIG. 5. HCV specificity of expanded FoxP3 Tregs demonstrated by MHC-II peptide tetramers. (A) Antigen specificities for HLA DRB1*04-
restricted class II tetramers bound to influenza virus hemagglutinin (Flu HA), HCV NS3 1248, and HCV NS4 1770 epitopes in short-term
peptide-stimulated T-cell lines are shown. (B) Specific binding of class II tetramers is shown by staining an HCV NS3/4-stimulated T-cell line with
isotype antibody, HCV NS4 1770 tetramer, and influenza virus HA-specific tetramer. An HCV NS3/4-specific T-cell line binds HCV 1770 but not
influenza virus HA tetramer. (C) Expansion of HCV-specific FoxP3 CD4 T cells in vitro. CFSE-labeled PBMC from a DRB1*04 HCV-
seropositive subject (R19) were stimulated with recombinant HCV NS3/4 protein, with the expansion of FoxP3 CD4 T cells (left panels) and
HCV-specific (but not influenza virus HA-specific) DRB1*04-restricted class II tetramer CD4 T cells (middle three panels). Circled gates indicate
class II tetramer CFSElow CD4 T cells that divided following antigenic stimulation. FACS plots on the far right show FoxP3 expression in the
gated HCV 1770-specific CFSElow CD4 T cells. (D) FoxP3 expression by influenza virus HA tetramer CD4 T cells is shown in CFSE-labeled PBL
following antigenic influenza virus HA peptide stimulation (gated on CD4 T cells on the upper graph) is shown. (Bottom) FoxP3 expression by
51% of gated CFSElow influenza virus tetramer (Tet) CD4 T cells in an overlay with total CD4.
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on a per cell basis. Collectively, these results show that FoxP3
Tregs rather than activated CD25 effector T cells are upregu-
lated in HCV infection.
The remarkable similarity between CD25 Tregs from HCV-
infected and uninfected subjects raises the possibility that natural
Tregs are expanded in HCV infection. However, FoxP3 expres-
sion and suppressive function can also be induced de novo in
CD4CD25 T cells following CD3/CD28 or antigenic stimula-
tion, particularly in the setting of TGF- or IFN-	 (16, 65, 66).
Based on combined analysis of T-cell turnover and clonality, it has
been suggested that a proportion of FoxP3 Tregs include an
adaptive population that differentiates from rapidly dividing
memory CD4 T cells rather than natural Tregs (1, 64). The pro-
gressive increase in memory and activation marker expression
from CD25 to CD25 FoxP3 and CD25 FoxP3 CD4 T cells
in our subjects may be consistent with a continuum between
memory and regulatory T cells. Consistent with the notion of
adaptive Tregs, HCV-specific FoxP3 Tregs could be expanded
in vitro in an antigen-specific manner from HCV-seropositive
persons. HCV-specific FoxP3 Tregs were also detected ex vivo,
albeit in limited cases with only low levels of FoxP3 expression.
Along these lines, antigen-specific expansion of FoxP3 memory/
effector T cells as well as FoxP3 regulatory T cells has been
reported for CD8 T cells (9). Treg induction may be enhanced by
HCV gene products with immune regulatory capacities as well as
increased circulating levels of TGF- (2, 41, 46), an immune
regulatory cytokine which is known to enhance adaptive Treg
induction (16, 65, 66). Although Treg frequency is not upregu-
lated ex vivo in HCV-recovered subjects (54), HCV-specific Tregs
could also be expanded in vitro from HCV-recovered subjects
(e.g., R58 and R23), suggesting that they may be maintained at a
low frequency in vivo but expand upon antigenic stimulation,
similar to memory T cells. While FoxP3 can be expressed by
activated human T cells (3), HCV-specific FoxP3 T cells in our
study were functional Tregs based on their ability to suppress
effector CD8 T-cell proliferation. FoxP3 expression was also de-
tected in CD4 T cells specific for non-HCV antigens (e.g., influ-
enza virus HA or tetanus toxoid), suggesting that immune regu-
lation via antigen-specific Tregs may extend beyond HCV. While
antigen-specific Tregs have been reported in the context of T-cell
receptor-transgenic animals or de novo induction (37, 60, 65, 68),
this is the first direct demonstration of antigen-specific FoxP3
Tregs using class II tetramers in human infection to our knowl-
edge.
FIG. 6. Detection of antigen-specific FoxP3 CD4 T cells ex vivo. (A) Staining strategy to reduce nonspecific background staining for class II
tetramers. CD4 and class II tetramer staining characteristics for freshly isolated PBL in subjects with and without the HLA DRB1*04 allele are
shown. Top graphs represent 7-amino-actinomycin-negative cells with lymphoid gate based on forward and side scatter characteristics. Bottom
graphs represent lymphoid cells with further exclusion of CD14 and/or CD19 cells. Flu HA, influenza virus HA. (B) FoxP3 expression in
antigen-specific CD4 T cells ex vivo. FoxP3 expression relative to HCV 1770 and influenza virus-specific class II tetramer staining is shown for two
patients with chronic HCV infection (C193 and C19). Percentages show relative FoxP3 expression among tetramer cells. (C) Enrichment of HCV
NS4 1770-specific class II tetramer CD4 T cells by magnetic beads using freshly isolated PBMC from an HCV-seropositive subject (17, 33), gating
on CD4 CD14 CD19 Viaprobe lymphoid cells. The multicolor FACS plots show that an obvious cluster of tetramer CD4 T cells can be seen
after (3.37%) but not before (0.00336%) tetramer enrichment (tetramer CD4; boxes). (D) FoxP3 expression in gated HCV NS4 1770-specific
class II tetramer CD4 T cells following enrichment. The upper histogram of tetramer CD4 T cells shows that 11.6% of gated HCV 1770-specific
tetramer CD4 T cells (red line) are FoxP3, based on the cutoff below which 99.8% of the isotype antibody-stained control sample (gray shaded
region) is negative. The lower FACS plot shows FoxP3 expression by gated tetramer CD4 T cells overlaid onto a density plot for CD14 CD19
7-amino-actinomycin-negative lymphocytes. Specifically, 11 events were positive for FoxP3, compared to 84 events negative for FoxP3.
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Induction of virus-specific Tregs can provide more-targeted
immune regulation at the site of infection and inflammation,
similar to the greater protection against autoimmune diabetes
in nonobese diabetic mice by Tregs specific for pancreatic islet
antigen than by polyclonally expanded Tregs (37, 38). Since
CD25 Tregs require activation through the T-cell receptor to
become suppressive (61), antigen-specific Tregs may become
suppressive in vivo only after encountering antigen-presenting
cells expressing their cognate antigens (e.g., in lymphoid tissue
during immune induction or in HCV-infected liver). As the
effector T cells home to the site of antigen expression, activa-
tion of antigen-specific Tregs (e.g., by HCV or even influenza
virus) in close proximity to the effector T cells will provide local
rather than global immune regulation to limit immune-medi-
ated damage while promoting viral persistence.
The ratio between CD25high and CD25int T cells correlated
positively with viremia in HCV-infected patients (P  0.009),
suggesting that the balance between Tregs and effector T cells
determines the level of viremia. Similar correlation was not
observed for serum liver transaminase levels, perhaps due to
generally well-preserved liver function among our study sub-
jects. Nevertheless, the accelerated liver disease progression in
HCV-infected patients with HIV coinfection (39, 57) suggests
that an HIV-associated CD4 T-cell defect may limit Treg-
mediated immune regulation and tilt the balance toward
pathogenetic effector T-cell response. In this respect, adoptive
transfer of antigen-specific Tregs may be a useful immunother-
apeutic strategy to limit the immune-mediated damage in
HCV infection, if combined with antiviral strategies to reduce
HCV replication. Further studies are needed to examine the
role of Tregs in liver disease pathogenesis and to develop
therapeutic approaches to control the balance between Tregs
and effector T cells to enhance viral clearance while limiting
liver inflammation.
In conclusion, functionally active FoxP3 Tregs are upregu-
lated ex vivo in HCV persistence. FoxP3 Tregs in HCV-
infected patients are phenotypically, functionally, and geneti-
cally indistinguishable from FoxP3 Tregs in uninfected
persons, and they include HCV-specific FoxP3 Tregs that
provide more-targeted virus-specific immune regulation. We
also provide a novel demonstration of HCV-specific FoxP3
Tregs using class II tetramers. These findings provide new
insights into antigen-specific immune regulation during viral
infection with potential therapeutic application.
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